Company intelligence / Profile preview

EMS Sigma Pharma

Hortolândia, São Paulo, Brazilems.com.br ↗

Ownership: Private
Employees: ~6000
Development stage: Other

Overview

EMS is the largest domestic pharmaceutical company in Brazil with a broad commercial portfolio spanning generics and branded drugs. It operates across multiple therapeutic areas and has several marketed products as well as ongoing clinical trials. The company is certified by the European Medicines Agency and exports to over 40 countries. Clinical results include participation in major studies such as pooled analyses of azithromycin safety for COVID‑19 patients[1][2][4].

Therapeutic areas: NeurologyInfectious DiseasesDermatologyEndocrinologyImmunologyCardiovascular
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Joint ventures and strategic partnerships with other pharmaceutical companies globally; specifics not publicly detailed for this division

Beyond the preview

Go deeper on EMS Sigma Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMS Sigma Pharma.

Explore the full profile